US74019L6020
US74019L6020
Precipio, Inc.
Loading chart...
Company Profile
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Latest News

Zacks • 09/22/2026
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Zacks • 09/10/2026
Top Research Reports for Goldman Sachs, RTX & Abbott

Zacks • 08/24/2026
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Zacks • 08/21/2026
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
GuruFocus.com • 08/21/2026
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
74.3% p.a.
Max Drawdown (5Y)
-91.7%
Sharpe Ratio (5Y)
-0.23
Beta Factor
1.30
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 59.3 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (74.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.9% in the extended horizon.